Age at time of treatment: 36 – 45
Injury Level: C6
Treatment Received: Stem Cells, Epidural Stimulation
Location of Treatment: Thailand
Time between injury and treatment: < 1 year
Date of Surgery: 16/09/2018
Date of Discharge: 02/11/2018
Patient sustained a traumatic spinal cord injury at C6 level on February 14, 2018. Patient has limited arm and hand function, but no finger function. He suffers mild spasms and spasticity, but no neuropathic pain. He requires assistance in his daily activities.
N/A
Patient sustained a traumatic spinal cord injury at C6 level on February 14, 2018. Patient has limited arm and hand function, but no finger function. He suffers mild spasms and spasticity, but no neuropathic pain. He requires assistance in his daily activities.
After a spinal MRI scan, EMG, and comprehensive blood work, patient underwent laminectomy and implantation of the epidural stimulation device on September 16, 2018. The device is the ‘Medtronic Restore Advance 16-electrode MRI Compatible Device’. The surgery was completed without significant adverse events and no serious complications were reported during the postoperative hospital stay. Surgical wounds healed normally and no spinal cord or superficial wound infection was reported.
After epidural stimulation surgery, patient received 124 mapping sessions and 35 physical therapy sessions. Patient also received 120 million Stem Cells: 40 million Mesenchymal Stem Cells (MSCs) and 80 million Amniotic Fluid Stem Cells (hAFSCs) through one IV injection and two lumbar puncture injections, respectively. All three applications went well without adverse effects and no short-term or acute complications have been reported.
Device mapping and therapy were carried out after surgery for 35 days, then the patient was discharged.
Improvements are monitored in 15 targeted areas: 11 Motor areas and 4 Sensory areas. However, the number of targeted areas may vary depending on patient’s condition prior to admission. If patient does not experience symptoms in certain Motor/Sensory functions, or is not impaired in a specific targeted area prior to surgery, it is excluded from the report (Not Applicable). If there is progress in any given area — either mild, moderate, or significant — it is measured and reported as positive (“Yes”). No improvement, the existence of pain or spasms, or an inability to perform a measured function is reported as “No”.
Motor function improved in 10 out of 11 targeted areas when the epidural stimulation device was switched on.
Patient does not suffer from neuropathic pain, therefore only 2 out of 3 sensory function areas were measured. Patient has not experienced any changes in those two sensory function areas, but more feedback will be collected after 3 months to note any improvements made by stem cell treatment.
Patient’s bowel control improved and his blood pressure increased to normal levels when the epidural stimulation device was switched on. Therefore, 2 out of 3 autonomic functions have improved. Overall, improvements were recorded in 12 out of 16 targeted motor, sensory and autonomic function areas.
epiduralstimulationnow.com is owned by Verita Neuro Pte. Ltd. Verita Neuro provides access to progressive, responsible healthcare to increase the quality of life. Verita Neuro partners with leading-edge, next-generation treatment providers, unique products and services, that are integrative, safe and effective. Verita Neuro is not a treatment provider.
All medical treatments have varied outcomes. Results from the treatments will vary from patient to patient. All examples of what has been achieved by others should not be taken as typical or in any way a guarantee or projection of what any individual can expect from treatment.